Fosamax Related Published Studies
Well-designed clinical trials related to Fosamax (Alendronate)
Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. [2009.08]
A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis. [2009.06]
Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. [2009.06]
Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers. [2009.05]
Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments. [2009.05]
Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. [2009.04]
Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial. [2009.04]
Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis. [2009.02.15]
Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty. [2009.02]
Once-weekly oral medication with alendronate does not prevent migration of knee prostheses: A double-blind randomized RSA study. [2009.02]
Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease. [2009.01]
Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohorts. [2009.01]
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. [2009.01]
The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis. [2009]
Comparison of the analgesic effects of bisphosphonates: etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance. [2009]
Peripheral quantitative computed tomography is useful to monitor response to alendronate therapy in postmenopausal women. [2009]
Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments. [2008.12.15]
Isosorbide mononitrate versus alendronate for postmenopausal osteoporosis. [2008.12]
Alendronate is effective to treat bone loss in renal transplantation recipients. [2008.12]
A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus. [2008.12]
Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. [2008.12]
Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. [2008.11]
Vertebral strength changes in rheumatoid arthritis patients treated with alendronate, as assessed by finite element analysis of clinical computed tomography scans: a prospective randomized clinical trial. [2008.11]
Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial). [2008.10]
The effect of alendronate on progression of spinal osteophytes and disc-space narrowing. [2008.10]
Isosorbide mononitrate versus alendronate for postmenopausal osteoporosis. [2008.09.20]
Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. [2008.09.20]
Treatment of osteonecrosis of the hip: comparison of extracorporeal shockwave with shockwave and alendronate. [2008.09]
Alendronate Once Weekly for the Prevention and Treatment of Bone Loss in Canadian Adult Cystic Fibrosis Patients (CFOS Trial). [2008.07.18]
[Alendronate prevents steroid-induced osteoporosis in patients with rheumatic diseases] [2008.07.15]
Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. [2008.07]
Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. [2008.07]
Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease. [2008.06.07]
Alendronate/vitamin D(3) 70 mg/2800 IU with and without additional 2800 IU vitamin D(3) for osteoporosis: Results from the 24-week extension of a 15-week randomized, controlled trial. [2008.05.15]
Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). [2008.05]
Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. [2008.02.29]
The effect of alendronate on progression of spinal osteophytes and disc space narrowing. [2008.02.14]
Alendronate decreases TRACP 5b activity in osteoarthritic bone. [2008.01.23]
Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. [2008.01]
Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K(2) in postmenopausal women. [2008]
Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature. [2008]
Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol. [2008]
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. [2007.11.30]
Teriparatide or alendronate in glucocorticoid-induced osteoporosis. [2007.11.15]
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. [2007.07]
Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. [2007.06]
Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial. [2007.05]
Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis. [2007.05]
Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. [2007.04]
Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. [2007.03.20]
Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). [2007.03]
Application of a semi-automated 96-well format solid-phase extraction, column-switching, fluorescence detection protocol for the determination of alendronate in human urine samples obtained from a bioequivalence study. [2007.02.19]
Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. [2007.01]
Alendronate inhibits periprosthetic bone loss around uncemented femoral components. [2007]
The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women. [2007]
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. [2006.12.27]
Effects of a combined alendronate and calcitriol agent (Maxmarvil(R)) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. [2006.12]
Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial. [2006.09]
Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. [2006.08.17]
Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. [2006.08]
Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. [2006.08]
Alendronate prevents femoral periprosthetic bone loss following total hip arthroplasty: prospective randomized double-blind study. [2006.07]
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. [2006.07]
Alendronate and vitamin D2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial. [2006.07]
[Effects of alendronate on bone mineral density, cytokines and indices of bone metabolism in postmenopausal osteoporotic patients] [2006.07]
Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women. [2006.06]
Randomized active and placebo-controlled endoscopy study of a novel protected formulation of oral alendronate. [2006.05]
Effects of alendronate and hormone replacement therapy, alone and in combination, on saliva, periodontal conditions and gingival crevicular fluid matrix metalloproteinase-8 levels in women with osteoporosis. [2006.03]
The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. [2006.03]
Effects of Oral Alendronate on BMD in Adult Patients With Osteogenesis Imperfecta: A 3-Year Randomized Placebo-Controlled Trial. [2006.02]
Three-year changes in bone mineral density around the knee after a six-month course of oral alendronate following total knee arthroplasty. A prospective, randomized study. [2006.02]
Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. [2006.02]
Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. [2006.01]
Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis. [2006.01]
In vitro disintegration and dissolution and in vivo bioequivalence of two alendronate once-weekly formulations. [2006]
Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial. [2006]
Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation. [2006]
Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis. [2005.12.31]
Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). [2005.12]
Alendronate for osteoporosis in men with androgen-repleted hypogonadism. [2005.12]
Impact of alendronate on quality of life in children with osteogenesis imperfecta. [2005.11]
The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin. [2005.11]
The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. [2005.10]
Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. [2005.10]
Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. [2005.10]
A randomized, placebo-controlled, 6-month study of once-weekly alendronate oral solution for postmenopausal osteoporosis. [2005.09]
Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women. [2005.09]
Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial. [2005.09]
Monitoring alendronate and estradiol therapy with quantitative ultrasound and bone mineral density. [2005.09]
Similar proportions of women lose bone mineral density with raloxifene or alendronate treatment. [2005.09]
Daily and cyclic parathyroid hormone in women receiving alendronate. [2005.08.11]
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. [2005.08.11]
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. [2005.08.08]
Effects of short-term alendronate on bone mineral density in haemodialysis patients. [2005.08]
Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. [2005.08]
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. [2005.07]
Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. [2005.07]
Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. [2005.07]
Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. [2005.06]
Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial. [2005.06]
Effect of alendronate on bone mineral density in spinal cord injury patients: a pilot study. [2005.06]
|
